2021-10-26| Licensing

Vertex Signs $700 Million worth CRISPR Pact with Jennifer Doudna Co-founded Gene Editing Firm

by Rajaneesh K. Gopinath
Share To
In April, Vertex amended a 2017 deal it signed with CRISPR Therapeutics to work on CTX001, a CRISPR-based therapy for beta-thalassemia and sickle cell disease. Vertex agreed to pay a whopping $900 million upfront to reap the majority profit from future sales of the drug. Now the company is investing close to $700 million on another CRISPR deal.

On October 26th, Vertex announced a new partnership with Mammoth Biosciences to develop in vivo gene-editing therapies for two genetic diseases using Mammoth's next-generation CRISPR systems.

"Vertex and Mammoth share the same commitment to developing therapies that have the potential to be transformative for people with serious diseases," said David Altshuler, M.D., Ph.D., CSO of Vertex Pharmaceuticals. "We look forward to expanding our cell and genetic therapies capabilities with the addition of Mammoth's ultra-small CRISPR systems for in vivo genome editing, which will provide us with another set of tools to tackle many of the diseases we're interested in.

GO Prime with only $1.49 now

Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top